NeuroBo Pharmaceuticals announced that the U.S. FDA has cleared its Investigational New Drug application for DA-1241, a novel G-Protein-Coupled Receptor 119 agonist. The company plans to initiate a two-part, Phase 2a clinical trial of DA-1241, for the treatment of nonalcoholic steatohepatitis, in the third quarter of 2023.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NRBO: